Brief: Genelux Corp Announces First Patient Dosed In Phase 2 Trial Evaluating Systemic Therapy With Olvi-Vec In Non-Small Cell Lung Cancer
22/10/2024 22:14
Oct 22 (Reuters) - Genelux Corp GNLX.O :
* GENELUX CORPORATION ANNOUNCES FIRST PATIENT DOSED IN PHASE
2
TRIAL EVALUATING SYSTEMIC THERAPY WITH OLVI-VEC IN NON-SMALL
CELL LUNG CANCER
* GENELUX CORP: INTERIM READOUT EXPECTED MID-2025
Source text for Eikon: ID:nGNX3L1yWW
Further company coverage: GNLX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genelux
See all newsGenelux posts wider-than-expected Q2 loss on higher R&D expenses
Genelux Corp expected to post a loss of 20 cents a share - Earnings Preview
Genelux Q1 net loss widens, misses analyst expectations
Brief: Genelux Corporation Announces Pricing Of $20.0 Million Underwritten Public Offering Of Common Stock
Brief: Genelux Corporation Announces Proposed Public Offering of Common Stock